Document is current

Article History

Received: 9 September 2017

Accepted: 3 February 2018

First Online: 12 February 2018

Compliance with ethical standards

:

: No author declares a direct conflict of interest related to this article. Sven Bölte discloses that he has in the last 5 years acted as an author, consultant, or lecturer for Shire, Medice, Roche, Eli Lilly, Prima Psychiatry, GLGroup, System Analytic, Kompetento, Expo Medica, and Prophase. He receives royalties for text books and diagnostic tools from Huber/Hogrefe, Kohlhammer, and UTB. David Coghill discloses that he has in the last 5 years acted as an author, consultant, or lecturer for Shire, Medice, Bristol Myers Squib, and Eli Lilly. He receives royalties for text books from Oxford University Press. Luis A Rohde was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Medice, Novartis, and Shire in the past 3 years. He receives authorship royalties from Oxford Press and ArtMed. He also received travel award to attend the 2015 WFADHD and 2016 AACAP meetings. The ADHD Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the past 3 years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. Petrus J de Vries has been on the study steering committee and advisory board for clinical trials and guideline development in tuberous sclerosis complex funded by Novartis.